{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T21:24:39Z","timestamp":1772918679894,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["GPP 2022"],"award-info":[{"award-number":["GPP 2022"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jclinepi.2025.111933","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T07:17:20Z","timestamp":1755501440000},"page":"111933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Including comparative observational evidence in trial-level surrogate endpoint evaluation: assessing relapse-free survival as a surrogate endpoint for overall survival in patients with acute myeloid leukemia post-transplant"],"prefix":"10.1016","volume":"187","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9008-6896","authenticated-orcid":false,"given":"Georgios F.","family":"Nikolaidis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasios","family":"Tasoulas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Gourgioti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Gro\u00df-Langenhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian J.A.","family":"Ridley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylwia","family":"Bujkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jclinepi.2025.111933_bib1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1177\/0272989X231162852","article-title":"Using Bayesian evidence synthesis methods to incorporate real-world evidence in surrogate endpoint evaluation","volume":"43","author":"Wheaton","year":"2023","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jclinepi.2025.111933_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2023.111242","article-title":"Surrogate endpoints: a key concept in clinical epidemiology","volume":"167","author":"Christensen","year":"2024","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.jclinepi.2025.111933_bib4","first-page":"10181","article-title":"Beyond overall survival: the value of oncology-relevant endpoints in HTA body\/payer decision-making","volume":"8","author":"Guti\u00e9rrez-Ibarluzea","year":"2023","journal-title":"J Oncol Res Ther"},{"key":"10.1016\/j.jclinepi.2025.111933_bib5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.leukres.2018.02.002","article-title":"Interpretation of clinical endpoints in trials of acute myeloid leukemia","volume":"68","author":"Medeiros","year":"2018","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.jclinepi.2025.111933_bib6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/annonc\/mdv562","article-title":"Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agents","volume":"27","author":"Saad","year":"2016","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.jclinepi.2025.111933_bib7","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.3390\/cancers13225722","article-title":"Management of acute myeloid leukemia: current treatment options and future perspectives","volume":"13","author":"Fleischmann","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jclinepi.2025.111933_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.612880","article-title":"FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies","volume":"10","author":"Kennedy","year":"2020","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.jclinepi.2025.111933_bib9","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jclinepi.2025.111933_bib10","article-title":"Hypomethylating agent-based combination therapies to treat post-hematopoietic stem cell transplant relapse of acute myeloid leukemia","volume":"11","author":"Ciotti","year":"2021","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.jclinepi.2025.111933_bib11","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3390\/cancers16071419","article-title":"Late relapse after allogeneic stem cell transplantation in patients treated for acute myeloid leukemia: relapse incidence, characteristics, role of conditioning regimen, and outcome","volume":"16","author":"Antier","year":"2024","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.jclinepi.2025.111933_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70026","article-title":"Long-term outcome of 2-year survivors after allogeneic hematopoietic cell transplantation for acute leukemia","volume":"8","author":"Larue","year":"2024","journal-title":"Hemasphere"},{"issue":"8","key":"10.1016\/j.jclinepi.2025.111933_bib13","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3324\/haematol.2010.039131","article-title":"Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission","volume":"96","author":"Buyse","year":"2011","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.jclinepi.2025.111933_bib14","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/SLA.0000000000006084","article-title":"Surrogacy of recurrence-free survival for overall survival as an endpoint of clinical trials of perioperative adjuvant therapy in hepatobiliary-pancreatic cancers: a retrospective study and meta-analysis","volume":"279","author":"Imamura","year":"2023","journal-title":"Ann Surg"},{"key":"10.1016\/j.jclinepi.2025.111933_bib15","author":"Bujkiewicz"},{"issue":"3","key":"10.1016\/j.jclinepi.2025.111933_bib16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jval.2016.10.011","article-title":"Time to review the role of surrogate end points in health policy: state of the art and the way forward","volume":"20","author":"Ciani","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.jclinepi.2025.111933_bib17","article-title":"Raising the bar for using surrogate endpoints in drug regulation and health technology assessment","volume":"374","author":"Dawoud","year":"2021","journal-title":"BMJ"},{"issue":"10450","key":"10.1016\/j.jclinepi.2025.111933_bib18","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0140-6736(24)01306-0","article-title":"SPIRIT-Surrogate and CONSORT-Surrogate Project team and Consensus Group. Transparent and complete reporting of surrogate endpoints in trials: the SPIRIT-surrogate and CONSORT-surrogate extensions","volume":"404","author":"Manyara","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2025.111933_bib19","series-title":"Statistics for biology and health: the evaluation of surrogate endpoints","doi-asserted-by":"crossref","DOI":"10.1007\/b138566","author":"Burzykowski","year":"2005"},{"issue":"5","key":"10.1016\/j.jclinepi.2025.111933_bib20","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/10543406.2015.1094811","article-title":"Statistical approaches for evaluating surrogate outcomes in clinical trials: a systematic review","volume":"26","author":"Ensor","year":"2016","journal-title":"J Biopharm Stat"},{"issue":"2","key":"10.1016\/j.jclinepi.2025.111933_bib21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/sim.2319","article-title":"Statistical evaluation of biomarkers as surrogate endpoints: a literature review","volume":"25","author":"Weir","year":"2006","journal-title":"Stat Med"},{"issue":"17","key":"10.1016\/j.jclinepi.2025.111933_bib22","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/(SICI)1097-0258(19970915)16:17<1965::AID-SIM630>3.0.CO;2-M","article-title":"Meta-analysis for the evaluation of potential surrogate markers","volume":"16","author":"Daniels","year":"1997","journal-title":"Stat Med"},{"issue":"5","key":"10.1016\/j.jclinepi.2025.111933_bib23","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1177\/0962280215597260","article-title":"Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints","volume":"26","author":"Bujkiewicz","year":"2017","journal-title":"Stat Methods Med Res"},{"issue":"22","key":"10.1016\/j.jclinepi.2025.111933_bib24","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1002\/sim.5831","article-title":"Multivariate meta-analysis of mixed outcomes: a Bayesian approach","volume":"32","author":"Bujkiewicz","year":"2013","journal-title":"Stat Med"},{"issue":"8","key":"10.1016\/j.jclinepi.2025.111933_bib25","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/sim.8465","article-title":"Bayesian hierarchical meta-analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data","volume":"39","author":"Papanikos","year":"2020","journal-title":"Stat Med"},{"issue":"5","key":"10.1016\/j.jclinepi.2025.111933_bib26","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred Reporting Items for Systematic reviews and Meta-Analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"10.1016\/j.jclinepi.2025.111933_bib27","author":"Higgins"},{"key":"10.1016\/j.jclinepi.2025.111933_bib28","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jclinepi.2025.111933_bib29","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jclinepi.2025.111933_bib30","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/sim.7991","article-title":"Model averaging for robust extrapolation in evidence synthesis","volume":"38","author":"R\u00f6ver","year":"2019","journal-title":"Stat Med"},{"issue":"28","key":"10.1016\/j.jclinepi.2025.111933_bib31","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1002\/sim.6728","article-title":"The power prior: theory and applications","volume":"34","author":"Ibrahim","year":"2015","journal-title":"Stat Med"},{"issue":"43","key":"10.1016\/j.jclinepi.2025.111933_bib36","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw"},{"key":"10.1016\/j.jclinepi.2025.111933_bib37","author":"Kay"},{"key":"10.1016\/j.jclinepi.2025.111933_bib38","series-title":"Modern Applied Statistics with S","author":"Venables","year":"2002"},{"key":"10.1016\/j.jclinepi.2025.111933_bib39","author":"Wickham"},{"key":"10.1016\/j.jclinepi.2025.111933_bib40","author":"Vehtari"},{"key":"10.1016\/j.jclinepi.2025.111933_bib41","author":"Vehtari"},{"key":"10.1016\/j.jclinepi.2025.111933_bib42","author":"Vehtari"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.111933_bib43","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1182\/blood-2019-128316","article-title":"Hypomethylating agent maintenance therapy after allogeneic stem cell transplant improves transplant outcome in high risk acute myelogenous leukemia","volume":"134","author":"Keruakous","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jclinepi.2025.111933_bib44","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/bloodadvances.2022008991","article-title":"Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R\/R FLT3mut AML","volume":"7","author":"Terao","year":"2023","journal-title":"Blood Adv"},{"issue":"15","key":"10.1016\/j.jclinepi.2025.111933_bib45","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jclinepi.2025.111933_bib46","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","article-title":"Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia","volume":"56","author":"Maziarz","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"26","key":"10.1016\/j.jclinepi.2025.111933_bib47","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.111933_bib48","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s12916-022-02479-x","article-title":"Effect of sorafenib maintenance on epstein-barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial","volume":"20","author":"Xu","year":"2022","journal-title":"BMC Med"},{"issue":"9","key":"10.1016\/j.jclinepi.2025.111933_bib49","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.jclinepi.2025.111933_bib50","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"issue":"36","key":"10.1016\/j.jclinepi.2025.111933_bib51","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.19.03277","article-title":"Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial","volume":"38","author":"Gao","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jclinepi.2025.111933_bib52","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1080\/10428194.2020.1789630","article-title":"Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia","volume":"61","author":"Ali","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.111933_bib53","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2991\/chi.d.190310.001","volume":"1","author":"Bazarbachi","year":"2019","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.jclinepi.2025.111933_bib54","first-page":"19","article-title":"Prophylactic or preemptive therapy with sorafenib after allogeneic hematopoietic cell transplantation improves overall survival of FLT3 AML patients","volume":"53","author":"Bazarbachi","year":"2019","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"10.1016\/j.jclinepi.2025.111933_bib55","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.14260","article-title":"Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission","volume":"175","author":"Brunner","year":"2016","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.jclinepi.2025.111933_bib56","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/s41409-019-0493-5","article-title":"Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival","volume":"54","author":"Chappell","year":"2019","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"10.1016\/j.jclinepi.2025.111933_bib57","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/ejh.13692","article-title":"Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: real-world treatment patterns and outcomes","volume":"107","author":"Griffin","year":"2021","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.111933_bib58","first-page":"2593","article-title":"FLT3 ITD AML outcomes are impacted by exposure to one cycle of cytarabine based consolidation, pre- and post-transplant TKI therapy, and presence of minimal residual disease (MRD) prior to allogeneic blood or marrow transplant","volume":"130","author":"Rebechi","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jclinepi.2025.111933_bib59","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/bjh.15691","article-title":"Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT","volume":"184","author":"Schmid","year":"2019","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.jclinepi.2025.111933_bib60","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1080\/10428194.2021.1913145","article-title":"Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients - a multicenter retrospective observational study","volume":"62","author":"Shimony","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.jclinepi.2025.111933_bib61","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00277-022-04821-y","article-title":"Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation","volume":"101","author":"Wattebled","year":"2022","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.111933_bib62","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1182\/blood-2021-149436","article-title":"Impact of concomitant genetic abnormalities on sorafenib therapy in FLT3-ITD positive acute myeloid leukemia undergoing allo-HSCT","volume":"138","author":"Shao","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jclinepi.2025.111933_bib63","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.bbmt.2019.03.027","article-title":"Donor-derived cytokine-induced killer cell infusion as consolidation after nonmyeloablative allogeneic transplantation for myeloid neoplasms","volume":"25","author":"Narayan","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"10.1016\/j.jclinepi.2025.111933_bib64","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","article-title":"Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD","volume":"133","author":"Schlenk","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jclinepi.2025.111933_bib65","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","article-title":"Random-effects model for meta-analysis of clinical trials: an update","volume":"28","author":"DerSimonian","year":"2007","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.jclinepi.2025.111933_bib66","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.jclinepi.2025.111933_bib67","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.3324\/haematol.2015.138552","article-title":"Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON\/SAKK, MRC\/NCRI","volume":"101","author":"Othus","year":"2016","journal-title":"Hematologica"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435625002665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435625002665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:27:47Z","timestamp":1772854067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435625002665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":62,"alternative-id":["S0895435625002665"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2025.111933","relation":{},"ISSN":["0895-4356"],"issn-type":[{"value":"0895-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Including comparative observational evidence in trial-level surrogate endpoint evaluation: assessing relapse-free survival as a surrogate endpoint for overall survival in patients with acute myeloid leukemia post-transplant","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2025.111933","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111933"}}